Network meta-analysis: efficacy and safety of treatments for fistulising Crohn’s disease

Abstract

Introduction Fistulas are a debilitating complication of Crohn’s disease and treatment options remain limited. There is a lack of head-to-head comparisons between treatments. To our knowledge, this is the first network meta-analysis on the efficacy of medical therapies in achieving fistula remission and maintenance of fistula closure in Crohn’s disease. Methods Biomedical databases and the Cochrane Central Registry were searched between 1978 and 2022 for randomized controlled trials (RCTs) reporting on treatments. A network meta-analysis was performed using the frequentist model with pooled relative risks (RRs) and P-scores used to rank treatments. Results Twenty-five RCTs were included for analysis with 2239 patients included. At the 16–24 week time point, infliximab produced the only statistically significant result with the 5 mg/kg dose proving the most effective [RR, 2.30; 95% confidence interval (CI), 1.40–3.77]. At 44 weeks, ustekinumab was found to be most superior with it being 2.38 times (RR, 2.38; 95% CI, 1.24–4.56) more superior to placebo, with adalimumab (RR, 2.06; 95% CI, 1.06–3.99) and infliximab 5 mg/kg (RR, 1.68; 95% CI, 1.03–2.75) also producing a statistically significant result. Conclusion Despite infliximab being favoured in international guidelines for the treatment of perianal fistulising Crohn’s disease, biologics such as ustekinumab, vedolizumab and adalimumab show promising results.